Pevonedistat
Based on 220 publication(s) in Google Scholar
Pevonedistat (MLN4924) is a potent and selective NEDD8-activating enzyme (NAE) inhibitor with an IC50 of 4.7 nM. Pevonedistat induces the deregulation of S-phase DNA synthesis, thereby disrupting protein turnover mediated by cullin-RING ligase, leading to apoptosis of human tumor cells. Pevonedistat suppresses the growth of human tumour xenografts in mice.
For research use only. We do not sell to patients.
- Purity: 99.55%
- CAS No.: 905579-51-3
- Formula: C21H25N5O4S
- Molecular Weight:443.52
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Pevonedistat
More- Signal Transduct Target Ther. 2025 Sep 26;10(1):310. [Abstract]
- Signal Transduct Target Ther. 2024 Jan 15;9(1):18. [Abstract]
- Nature. 2026 Jan;649(8098):1032-1041. [Abstract]
- Nature. 2025 Jul;643(8073):1107-1116. [Abstract]
- Nature. 2025 Feb;638(8050):519-527. [Abstract]
- Nature. 2020 Dec;588(7836):164-168. [Abstract]
- Cancer Cell. 2025 Jul 25:S1535-6108(25)00310-1. [Abstract]
- Cancer Cell. 2025 Jun 10:S1535-6108(25)00220-X. [Abstract]
- Cancer Cell. 2020 Mar 16;37(3):371-386.e12. [Abstract]
- Cell. 2023 Apr 27;186(9):1895-1911.e21. [Abstract]
- Cell. 2019 Jul 11;178(2):330-345.e22. [Abstract]
- Cancer Discov. 2026 Apr 19. [Abstract]
- Cell Metab. 2023 Sep 5;35(9):1630-1645.e5. [Abstract]
- Nat Cancer. 2021 Apr;2(4):429-443. [Abstract]
- Cell Res. 2021 Mar;31(3):291-311. [Abstract]
- Cell Stem Cell. 2024 Jun 21:S1934-5909(24)00210-8. [Abstract]
- Bioact Mater. 2024 Jan 6:34:366-380. [Abstract]
- Nat Microbiol. 2019 May;4(5):813-825. [Abstract]
- Mol Cell. 2023 Dec 7;83(23):4352-4369.e8. [Abstract]
- Mol Cell. 2022 Apr 7;82(7):1297-1312.e8. [Abstract]
- Nat Commun. 2026 May 13;17(1):4331. [Abstract]
- Nat Commun. 2026 Feb 12;17(1):1214. [Abstract]
- Nat Commun. 2025 Sep 16;16(1):8289. [Abstract]
- Nat Commun. 2025 Jul 24;16(1):6831. [Abstract]
- Nat Commun. 2024 Dec 3;15(1):10536. [Abstract]
- Nat Commun. 2024 Aug 17;15(1):7089. [Abstract]
- Nat Commun. 2024 Jul 3;15(1):5604. [Abstract]
- Nat Commun. 2024 Jun 26;15(1):5409. [Abstract]
- Nat Commun. 2024 Jan 11;15(1):468. [Abstract]
- Nat Commun. 2022 Oct 10;13(1):5973. [Abstract]
- Nat Commun. 2022 Sep 2;13(1):5173. [Abstract]
- Nat Commun. 2021 Sep 10;12(1):5386. [Abstract]
- Nat Commun. 2018 Sep 18;9(1):3801. [Abstract]
- Nat Commun. 2017 May 22;8:15398. [Abstract]
- Cell Death Differ. 2022 Jan;29(1):1-13. [Abstract]
- Cell Death Differ. 2020 Apr;27(4):1383-1397. [Abstract]
- Acta Pharm Sin B. 2026 Feb 10.
- Adv Sci (Weinh). 2026 Apr;13(20):e15159. [Abstract]
- Adv Sci (Weinh). 2025 Oct 5:e03277. [Abstract]
- Adv Sci (Weinh). 2025 Aug 11:e11081. [Abstract]
- Nat Chem Biol. 2024 Dec;20(12):1640-1649. [Abstract]
- Nat Chem Biol. 2024 Sep;20(9):1227-1236. [Abstract]
- Nat Chem Biol. 2024 Jan;20(1):93-102. [Abstract]
- Nat Chem Biol. 2023 Dec;19(12):1513-1523. [Abstract]
- Nat Plants. 2019 Jan;5(1):34-40. [Abstract]
- Biomaterials. 2026 Jul:330:124045. [Abstract]
- Sci Adv. 2026 Feb 6;12(6):eadz3483. [Abstract]
- Sci Adv. 2024 Apr 12;10(15):eadm7600. [Abstract]
- Sci Adv. 2022 Sep 23;8(38):eabq4831. [Abstract]
- Redox Biol. 2021 Oct:46:102114. [Abstract]
- Cell Rep Med. 2024 Jul 16;5(7):101653. [Abstract]
- J Exp Med. 2018 Aug 6;215(8):1999-2017. [Abstract]
- Nat Struct Mol Biol. 2024 Feb;31(2):323-335. [Abstract]
- Cell Death Dis. 2025 Nov 17;16(1):843. [Abstract]
- Cell Death Dis. 2025 Aug 28;16(1):654. [Abstract]
- Cell Death Dis. 2025 Jul 31;16(1):579. [Abstract]
- Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):e2111737119. [Abstract]
- Dev Cell. 2019 Feb 11;48(3):329-344.e5. [Abstract]
- Int J Biol Macromol. 2025 Dec 30:150018. [Abstract]
- Int J Biol Macromol. 2025 May;306(Pt 3):141587. [Abstract]
- Int J Biol Macromol. 2024 Sep 17:135764. [Abstract]
- EMBO J. 2019 Dec 2;38(23):e101409. [Abstract]
- Cancer Immunol Res. 2025 Apr 22. [Abstract]
- ACS Environ Au. 2025 Aug 5;5(6):573-582. [Abstract]
- Neoplasia. 2022 Oct:32:100823. [Abstract]
- Cell Chem Biol. 2025 Apr 17;32(4):556-569.e24. [Abstract]
- Cell Chem Biol. 2021 Oct 21;28(10):1514-1527.e4. [Abstract]
- Cell Death Discov. 2025 Nov 3;11(1):496. [Abstract]
- Cell Death Discov. 2024 Oct 26;10(1):453. [Abstract]
- Cell Death Discov. 2022 Jul 12;8(1):316. [Abstract]
- Cell Death Discov. 2022 May 2;8(1):238. [Abstract]
- Cell Rep. 2026 Jun 2;45(6).
- Cell Rep. 2025 Nov 25;44(12):116602. [Abstract]
- Cell Rep. 2024 Feb 27;43(2):113749. [Abstract]
- Cell Rep. 2021 Aug 24;36(8):109568. [Abstract]
- Cell Rep. 2021 Jul 20;36(3):109394. [Abstract]
- J Med Chem. 2026 Jan 22;69(2):1119-1134. [Abstract]
- J Med Chem. 2025 Dec 31. [Abstract]
- J Med Chem. 2025 Apr 25. [Abstract]
- J Med Chem. 2024 Oct 24;67(20):18549-18575. [Abstract]
- J Med Chem. 2024 Oct 24;67(20):18247-18264. [Abstract]
- J Med Chem. 2024 Aug 8;67(15):12521-12533. [Abstract]
- J Med Chem. 2023 Sep 28;66(18):12877-12893. [Abstract]
- J Med Chem. 2023 Jul 13;66(13):9184-9200. [Abstract]
- J Med Chem. 2023 May 11;66(9):6070-6081. [Abstract]
- J Med Chem. 2022 Jan 13;65(1):747-756. [Abstract]
- J Med Chem. 2021 Jul 8;64(13):9152-9165. [Abstract]
- Clin Transl Med. 2020 Jun;10(2):e113. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- Sci Signal. 2025 Feb 11;18(873):eado2857. [Abstract]
- Mol Metab. 2021 Nov:53:101275. [Abstract]
- Elife. 2020 Jun 2;9:e54954. [Abstract]
- Elife. 2019 Mar 25:8:e45457. [Abstract]
- Elife. 2018 Aug 1;7:e38430. [Abstract]
- Elife. 2016 Apr 11;5:e14087. [Abstract]
- EMBO Rep. 2025 Mar;26(5):1344-1366. [Abstract]
- Cell Biosci. 2020 Nov 27;10(1):139. [Abstract]
- Cell Biol Toxicol. 2025 Mar 20;41(1):61. [Abstract]
- Eur J Med Chem. 2023 Nov 15:260:115732. [Abstract]
- Front Immunol. 2022 Jul 4;13:925702. [Abstract]
- Biochem Pharmacol. 2025 Jul 12:241:117159. [Abstract]
- Biochem Pharmacol. 2024 May:223:116198. [Abstract]
- Neurobiol Dis. 2020 Sep;143:105013. [Abstract]
- Virulence. 2026 Dec;17(1):2645908. [Abstract]
- Mol Ther Oncolytics. 2020 Jun 23;18:215-225. [Abstract]
- Cells. 2021 Oct 20;10(11):2803. [Abstract]
- Protein Sci. 2021 Nov;30(11):2338-2345. [Abstract]
- J Pathol. 2021 Jun;254(2):185-198. [Abstract]
- Cells. 2020 Mar 30;9(4):834. [Abstract]
- Commun Biol. 2021 Sep 13;4(1):1066. [Abstract]
- Inflammation. 2025 Mar 1. [Abstract]
- PLoS Pathog. 2025 Jul 3;21(7):e1013258. [Abstract]
- Int J Mol Sci. 2025 May 3;26(9):4361. [Abstract]
- Int J Mol Sci. 2025 Apr 17;26(8):3790. [Abstract]
- Int J Mol Sci. 2023 Feb 8;24(4):3415. [Abstract]
- Int Immunopharmacol. 2026 Apr 15:175:116421. [Abstract]
- Int Immunopharmacol. 2026 Mar 15:173:116274. [Abstract]
- Eur J Pharmacol. 2025 Sep 15:1003:177942. [Abstract]
- Eur J Pharmacol. 2025 Jan 9:177270. [Abstract]
- Int Immunopharmacol. 2024 Jul 21:139:112716. [Abstract]
- Bioorg Chem. 2024 Jun 24:150:107590. [Abstract]
- Mol Cancer Res. 2023 May 1;21(5):428-443. [Abstract]
- Biosci Rep. 2022 Aug 31;42(8):BSR20220994. [Abstract]
- Mbio. 2020 Jul 14;11(4):e00782-20. [Abstract]
- Cancers. 2019 Jan 15;11(1):97. [Abstract]
- Structure. 2026 Mar 20:S0969-2126(26)00056-0. [Abstract]
- Front Cell Dev Biol. 2021 Apr 30:9:667435. [Abstract]
- Lipids Health Dis. 2025 Oct 2;24(1):307. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Jul 12;1871(7):167985. [Abstract]
- FASEB J. 2021 Aug;35(8):e21800. [Abstract]
- Lab Invest. 2019 Apr;99(4):528-538. [Abstract]
- iScience. 2023 Mar 22;26(4):106468. [Abstract]
- Comput Struct Biotechnol J. 2021 Oct 1:19:5568-5577. [Abstract]
- J Cell Physiol. 2025 Jan;240(1):e31459. [Abstract]
- J Cell Physiol. 2022 Aug;237(8):3278-3291. [Abstract]
- J Biol Chem. 2026 Jun;302(6):111461. [Abstract]
- Sci Rep. 2025 May 30;15(1):18978. [Abstract]
- Sci Rep. 2025 Apr 25;15(1):14498. [Abstract]
- J Biol Chem. 2024 Jul 1:107512. [Abstract]
- J Biol Chem. 2022 Oct;298(10):102484. [Abstract]
- J Biol Chem. 2021 Nov;297(5):101307. [Abstract]
- J Virol. 2025 May 21:e0035425. [Abstract]
- J Virol. 2024 Feb 20;98(2):e0190923. [Abstract]
- J Virol. 2022 May 25;96(10):e0059822. [Abstract]
- Cell Signal. 2025 Jun:130:111665. [Abstract]
- J Cell Sci. 2025 Jun 18:jcs.263596. [Abstract]
- RSC Med Chem. 2025 Jun 19. [Abstract]
- Viruses. 2023 Nov 30;15(12):2356. [Abstract]
- Exp Cell Res. 2020 Jul 15;392(2):112038. [Abstract]
- Am J Physiol Lung Cell Mol Physiol. 2019 Jun 1;316(6):L1070-L1080. [Abstract]
- Am J Physiol Lung Cell Mol Physiol. 2017 Jul 1;313(1):L104-L114. [Abstract]
- J Immunol. 2021 Jul 1;207(1):296-307. [Abstract]
- Cell Cycle. 2019 Sep;18(18):2307-2322. [Abstract]
- Front Oncol. 2022 Jan 26;12:822039. [Abstract]
- Front Oncol. 2017 Dec 11:7:293. [Abstract]
- Int J Med Sci. 2018 Apr 3;15(7):674-681. [Abstract]
- Arch Biochem Biophys. 2022 May 30;721:109194. [Abstract]
- Arch Biochem Biophys. 2021 Oct 15:710:109000. [Abstract]
- J Anim Sci. 2024 Jan 3:102:skae251. [Abstract]
- Technol Cancer Res Treat. 2016 Aug;15(4):527-34. [Abstract]
- Theriogenology. 2025 Apr 15:237:99-109. [Abstract]
- Virology. 2015 Mar;477:10-7. [Abstract]
- Ann Hematol. 2014 Sep;93(9):1499-508. [Abstract]
- Cancer Chemother Pharmacol. 2018 Jun;81(6):1083-1093. [Abstract]
- Biochim Biophys Acta Gen Subj. 2025 Sep;1869(10):130842. [Abstract]
- Biochem Biophys Res Commun. 2021 Apr 16:549:150-156. [Abstract]
- Oncol Lett. 2019 Sep;18(3):2724-2732. [Abstract]
- Biochem Biophys Res Commun. 2019 Sep 3;516(4):1242-1247. [Abstract]
- Biochem Biophys Res Commun. 2019 Jan 15;508(3):986-990. [Abstract]
- Biochem Biophys Res Commun. 2018 Nov 17;506(1):108-113. [Abstract]
- Biochem Biophys Res Commun. 2017 Jan 29;483(1):223-229. [Abstract]
- Biosci Biotechnol Biochem. 2024 Nov 22;88(12):1432-1441. [Abstract]
- bioRxiv. 2026 May 6.
- bioRxiv. 2026 May 14:2026.05.12.724395. [Abstract]
- bioRxiv. 2026 Apr 30.
- bioRxiv. 2026 Mar 6.
- Technical University of Munich. 2025.
- bioRxiv. 2025 Oct 24.
- Patent. US20250276069A1.
- bioRxiv. 2025 Aug 28:2025.08.26.672429. [Abstract]
- bioRxiv. 2025 Aug 14:2025.08.14.670414. [Abstract]
- bioRxiv. 2025 Aug 20:2025.08.19.671158. [Abstract]
- bioRxiv. 2025 July 04.
- Harvard University. 2025.
- bioRxiv. 2025 Jun 19.
- bioRxiv. 2025 May 15:2025.05.10.653233. [Abstract]
- bioRxiv. 2025 May 17.
- bioRxiv. 2025 January 08.
- bioRxiv. 2024 November 28.
- bioRxiv. 2024 September 26.
- bioRxiv. 2024 Sep 27:2024.09.25.615094. [Abstract]
- University of Southern California. 2024.
- bioRxiv. 2024 Sep 19:2024.09.13.612935. [Abstract]
- bioRxiv. 2024 July 08.
- Patent. US20240190838A1.
- bioRxiv. 2024 June 12.
- University of Colorado Denver. 2024.
- University of Colorado Denver. 2024.
- bioRxiv. 2024 July 01.
- bioRxiv. 2024 Jan 28.
- bioRxiv. 2023 Jun 5.
- Harvard University. 2023 Mar. 30487357.
- bioRxiv. 2023 Feb 15:2023.02.14.528208. [Abstract]
- bioRxiv. 2023 Feb 21:2023.02.21.529401. [Abstract]
- Research Square Print. 2022.
- Patent. US20220378919A1.
- Patent. US20220280649A1.
- Patent. US20220281931A1.
- Research Square Preprint. 2022 Jul.
- Patent. US20220175722A1.
- Research Square Preprint. 2021 Jun.
- Institut für Pharmazeutische Wissenschaften. 2020 Nov.
- bioRxiv. April.
- Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8273-8280. [Abstract]
- Patent. US20180263995A1.
- Oncotarget. 2017 Oct 12;8(57):97178-97186. [Abstract]
- Oncotarget. 2017 Sep 23;8(49):86395-86409. [Abstract]
- Ulm University. 2017 Jan.
- Oncotarget. 2016 Oct 4;7(40):66087-66099. [Abstract]
- Oncotarget. 2016 Jun 14;7(24):35643-35654. [Abstract]
-
WB
-
IP
-
WB
-
WB
-
Cell Proliferation/Viability Assay
Biological Activity
IC50: 4.7 nM (NAE)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.63 μM
Compound: MLN4924
|
Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 33129593] |
| A549 | IC50 |
1.64 μM
Compound: MLN4924
|
Antiproliferative activity against human A549 cells by CCK8 assay
Antiproliferative activity against human A549 cells by CCK8 assay
|
[PMID: 38320715] |
| A549 | IC50 |
47.79 μM
Compound: MLN4924
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 34624825] |
| BEAS-2B | IC50 |
1.22 μM
Compound: MLN4924
|
Cytotoxicity against human BEAS-2B cells incubated for 48 hrs by CCK-8 assay
Cytotoxicity against human BEAS-2B cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 33129593] |
| Caco-2 | IC50 |
4.4 μM
Compound: MLN4924
|
Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay
Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay
|
[PMID: 29232579] |
| CAPAN-1 | IC50 |
101 nM
Compound: 1; MLN4924
|
Antiproliferative activity against human CAPAN-1 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
Antiproliferative activity against human CAPAN-1 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
[PMID: 33857374] |
| DU-145 | IC50 |
201 nM
Compound: 1; MLN4924
|
Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
[PMID: 33857374] |
| EKVX | IC50 |
>10 μM
Compound: MLN4924
|
Antiproliferative activity against human EKVX cells measured after 48 hrs by CCK8 assay
Antiproliferative activity against human EKVX cells measured after 48 hrs by CCK8 assay
|
[PMID: 31732254] |
| EKVX | IC50 |
0.3 μM
Compound: MLN4924
|
Antiproliferative activity against human EKVX cells measured after 72 to 96 hrs by CCK8 assay
Antiproliferative activity against human EKVX cells measured after 72 to 96 hrs by CCK8 assay
|
[PMID: 31732254] |
| GES1 | IC50 |
13.45 μM
Compound: MLN4924
|
Cytotoxicity against human GES1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Cytotoxicity against human GES1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 34624825] |
| HCT-116 | IC50 |
0.19 μM
Compound: MLN4924
|
Antitumor activity against human HCT116 cells after 72 hrs by MTT assay
Antitumor activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 28388520] |
| HCT-116 | IC50 |
33.89 nM
Compound: 1; MLN4924
|
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition by sulforhodamine B assay
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition by sulforhodamine B assay
|
[PMID: 33857374] |
| HCT-116 | IC50 |
36.2 nM
Compound: 1; MLN4924
|
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
[PMID: 33857374] |
| HepG2 | IC50 |
>10 μM
Compound: MLN4924
|
Antiproliferative activity against human HepG2 cells measured after 48 hrs by CCK8 assay
Antiproliferative activity against human HepG2 cells measured after 48 hrs by CCK8 assay
|
[PMID: 31732254] |
| HepG2 | IC50 |
0.3 μM
Compound: MLN4924
|
Antiproliferative activity against human HepG2 cells measured after 72 to 96 hrs by CCK8 assay
Antiproliferative activity against human HepG2 cells measured after 72 to 96 hrs by CCK8 assay
|
[PMID: 31732254] |
| HepG2 | IC50 |
8.15 μM
Compound: MLN4924
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 34624825] |
| HGC-27 | IC50 |
1.25 μM
Compound: MLN4924
|
Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 34624825] |
| HT-29 | IC50 |
484 nM
Compound: 1; MLN4924
|
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
[PMID: 33857374] |
| Huh-7 | IC50 |
>10 μM
Compound: MLN4924
|
Antiproliferative activity against human HuH7 cells measured after 48 hrs by CCK8 assay
Antiproliferative activity against human HuH7 cells measured after 48 hrs by CCK8 assay
|
[PMID: 31732254] |
| Huh-7 | IC50 |
0.3 μM
Compound: MLN4924
|
Antiproliferative activity against human HuH7 cells measured after 72 to 96 hrs by CCK8 assay
Antiproliferative activity against human HuH7 cells measured after 72 to 96 hrs by CCK8 assay
|
[PMID: 31732254] |
| HuTu80 | IC50 |
42.6 nM
Compound: 1; MLN4924
|
Antiproliferative activity against human HuTu80 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
Antiproliferative activity against human HuTu80 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
[PMID: 33857374] |
| Jurkat | IC50 |
152 nM
Compound: 1; MLN4924
|
Antiproliferative activity against human Jurkat cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
Antiproliferative activity against human Jurkat cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
[PMID: 33857374] |
| K562 | EC50 |
108 nM
Compound: 2, MLN4924
|
Antiproliferative activity against human K562 cells after 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human K562 cells after 72 hrs by CellTiter-Glo assay
|
[PMID: 24900352] |
| KYSE-30 | IC50 |
3.75 μM
Compound: MLN4924
|
Antiproliferative activity against human KYSE-30 cells by CCK8 assay
Antiproliferative activity against human KYSE-30 cells by CCK8 assay
|
[PMID: 38320715] |
| LNCaP-Clone-FGC | IC50 |
64.6 nM
Compound: 1; MLN4924
|
Antiproliferative activity against human LNCaP-Clone-FGC cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
Antiproliferative activity against human LNCaP-Clone-FGC cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
[PMID: 33857374] |
| MCF7 | IC50 |
>10 μM
Compound: MLN4924
|
Antiproliferative activity against human MCF7 cells measured after 48 hrs by CCK8 assay
Antiproliferative activity against human MCF7 cells measured after 48 hrs by CCK8 assay
|
[PMID: 31732254] |
| MCF7 | IC50 |
>100 μM
Compound: MLN4924
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 34624825] |
| MCF7 | IC50 |
0.3 μM
Compound: MLN4924
|
Antiproliferative activity against human MCF7 cells measured after 72 to 96 hrs by CCK8 assay
Antiproliferative activity against human MCF7 cells measured after 72 to 96 hrs by CCK8 assay
|
[PMID: 31732254] |
| MGC-803 | IC50 |
>10 μM
Compound: MLN4924
|
Antiproliferative activity against human MGC803 cells measured after 48 hrs by CCK8 assay
Antiproliferative activity against human MGC803 cells measured after 48 hrs by CCK8 assay
|
[PMID: 31732254] |
| MGC-803 | IC50 |
0.3 μM
Compound: MLN4924
|
Antiproliferative activity against human MGC803 cells measured after 72 to 96 hrs by CCK8 assay
Antiproliferative activity against human MGC803 cells measured after 72 to 96 hrs by CCK8 assay
|
[PMID: 31732254] |
| MGC-803 | IC50 |
1.84 μM
Compound: MLN4924
|
Antiproliferative activity against human MGC-803 cells by CCK8 assay
Antiproliferative activity against human MGC-803 cells by CCK8 assay
|
[PMID: 38320715] |
| MGC-803 | IC50 |
5.16 μM
Compound: MLN4924
|
Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 34624825] |
| MKN-45 | IC50 |
>10 μM
Compound: MLN4924
|
Antiproliferative activity against human MKN45 cells measured after 48 hrs by CCK8 assay
Antiproliferative activity against human MKN45 cells measured after 48 hrs by CCK8 assay
|
[PMID: 31732254] |
| MKN-45 | IC50 |
0.3 μM
Compound: MLN4924
|
Antiproliferative activity against human MKN45 cells measured after 72 to 96 hrs by CCK8 assay
Antiproliferative activity against human MKN45 cells measured after 72 to 96 hrs by CCK8 assay
|
[PMID: 31732254] |
| MV4-11 | IC50 |
107 nM
Compound: 1; MLN4924
|
Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
[PMID: 33857374] |
| NCI-H1299 | IC50 |
>10 μM
Compound: MLN4924
|
Antiproliferative activity against human H1299 cells measured after 48 hrs by CCK8 assay
Antiproliferative activity against human H1299 cells measured after 48 hrs by CCK8 assay
|
[PMID: 31732254] |
| NCI-H1299 | IC50 |
0.3 μM
Compound: MLN4924
|
Antiproliferative activity against human H1299 cells measured after 72 to 96 hrs by CCK8 assay
Antiproliferative activity against human H1299 cells measured after 72 to 96 hrs by CCK8 assay
|
[PMID: 31732254] |
| NCI-H1299 | IC50 |
0.49 μM
Compound: MLN4924
|
Antiproliferative activity against human H1299 cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human H1299 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 33129593] |
| PLC | IC50 |
>10 μM
Compound: MLN4924
|
Antiproliferative activity against human PLC cells measured after 48 hrs by CCK8 assay
Antiproliferative activity against human PLC cells measured after 48 hrs by CCK8 assay
|
[PMID: 31732254] |
| PLC | IC50 |
0.3 μM
Compound: MLN4924
|
Antiproliferative activity against human PLC cells measured after 72 to 96 hrs by CCK8 assay
Antiproliferative activity against human PLC cells measured after 72 to 96 hrs by CCK8 assay
|
[PMID: 31732254] |
| RKO | IC50 |
166 nM
Compound: 1; MLN4924
|
Antiproliferative activity against human RKO cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
Antiproliferative activity against human RKO cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
[PMID: 33857374] |
| T47D | IC50 |
>10 μM
Compound: MLN4924
|
Antiproliferative activity against human T47D cells measured after 48 hrs by CCK8 assay
Antiproliferative activity against human T47D cells measured after 48 hrs by CCK8 assay
|
[PMID: 31732254] |
| T47D | IC50 |
0.3 μM
Compound: MLN4924
|
Antiproliferative activity against human T47D cells measured after 72 to 96 hrs by CCK8 assay
Antiproliferative activity against human T47D cells measured after 72 to 96 hrs by CCK8 assay
|
[PMID: 31732254] |
| THP-1 | IC50 |
115 nM
Compound: 1; MLN4924
|
Antiproliferative activity against human THP-1 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
Antiproliferative activity against human THP-1 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
[PMID: 33857374] |
| U2OS | IC50 |
0.16 μM
Compound: MLN4924
|
Antitumor activity against human U2OS cells after 72 hrs by MTT assay
Antitumor activity against human U2OS cells after 72 hrs by MTT assay
|
[PMID: 28388520] |
Pevonedistat (MLN4924) is a potent inhibitor of NAE, and is selective relative to the closely related enzymes UAE, SAE, UBA6 and ATG7 (IC50=1.5, 8.2, 1.8 and >10 μM, respectively) when evaluated in purified enzyme assays that monitor the formation of E2-UBL thioester reaction products. Pevonedistat (MLN4924) selectively inhibits NAE activity compared to the closely related ubiquitin-activating enzyme (UAE, also known as UBA1) and SUMO-activating enzyme (SAE; a heterodimer of SAE1 and UBA2 subunits), in purified enzyme and cellular assays. MLN4924 exhibits potent cytotoxic activity against a variety of human tumour-derived cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 905579-51-3
-
Appearance Solid
-
Molecular Weight 443.52
-
Formula C21H25N5O4S
-
Color White to light yellow
-
SMILES
O=S(OC[C@@H]1C[C@@H](N2C3=NC=NC(N[C@H]4CCC5=C4C=CC=C5)=C3C=C2)C[C@@H]1O)(N)=O
-
Synonyms
MLN4924
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (220)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Reprogramming of cancer metabolism via photoresponsive nano-PROTAC enhances pyroptosis-mediated immunotherapy. [Abstract]2025 Sep 26;10(1):310. PMID: 40998785 -
Signal Transduct Target Ther
Neddylation is a novel therapeutic target for lupus by regulating double negative T cell homeostasis. [Abstract]2024 Jan 15;9(1):18. PMID: 38221551
Pevonedistat purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2024 Jan 15;9(1):18. [Abstract]
MLN4924 (0.1-0.5 μM; 12 h) remarkably inhibits the neddylation of Cullin1 in splenocytes of MRL/lpr mice.
Pevonedistat purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2024 Jan 15;9(1):18. [Abstract]
MLN4924 disrupts the ubiquitination-mediated degradation pathway of Bim in DN T cells, thereby promoting Bim accumulation.
Pevonedistat purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2024 Jan 15;9(1):18. [Abstract]
MLN4924-mediated neddylation inhibition promotes DN T cell apoptosis while increasing Bim and cleaved-caspase 3 protein levels.
-
Nature
2026 Jan;649(8098):1032-1041. PMID: 41299171 -
Nature
2025 Jul;643(8073):1107-1116. PMID: 40468084 -
Nature
2025 Feb;638(8050):519-527. PMID: 39880951 -
Nature
2020 Dec;588(7836):164-168. PMID: 33208943
Pevonedistat purchased from MedChemExpress. Usage Cited in: Nature. 2020 Dec;588(7836):164-168. [Abstract]
Immunoblots of BCL6 levels in SuDHL4Cas9 cells treated with DMSO, 10 μM MLN7243 (ubiquitin activating enzyme inhibitor), 10 μM MG132 (26S proteasome inhibitor), 10 μM Chloroquine (lysosomal inhibitor), or 5 μM MLN4924 (neddylation inhibitor) for 15 minutes, then, for indicated samples, 1 μM BI-3802 was added and 35 minutes later, 10 μM BI-3812 was added for the final 10 minutes, resulting in a total of 1 hour treatment with MLN7243, MG132, Chloroquine, and MLN4924, 45 minutes of BI-3802, and 10
-
Cancer Cell
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. [Abstract]2025 Jul 25:S1535-6108(25)00310-1. PMID: 40780213 -
Cancer Cell
Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling. [Abstract]2025 Jun 10:S1535-6108(25)00220-X. PMID: 40513576 -
Cancer Cell
2020 Mar 16;37(3):371-386.e12. PMID: 32109374 -
Cell
2023 Apr 27;186(9):1895-1911.e21. PMID: 37028429 -
Cell
2019 Jul 11;178(2):330-345.e22. PMID: 31257027 -
Cancer Discov
TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancers. [Abstract]2026 Apr 19. PMID: 42001523 -
Cell Metab
2023 Sep 5;35(9):1630-1645.e5. PMID: 37541251 -
Nat Cancer
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. [Abstract]2021 Apr;2(4):429-443. PMID: 34568836 -
Cell Res
2021 Mar;31(3):291-311. PMID: 33299139
Pevonedistat purchased from MedChemExpress. Usage Cited in: Cell Res. 2021 Mar;31(3):291-311. [Abstract]
MLN4924 (1 μM; 12 h). Immunoblot of WCL from MCF-7 cells transfected with Myc-PTEN (a), or tissues of WT or NEDP1 KO mice (b), or NEDP1-deleted MCF-7 cells (c).
-
Cell Stem Cell
Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration. [Abstract]2024 Jun 21:S1934-5909(24)00210-8. PMID: 38917806 -
Bioact Mater
Neddylation suppression by a macrophage membrane-coated nanoparticle promotes dual immunomodulatory repair of diabetic wounds. [Abstract]2024 Jan 6:34:366-380. PMID: 38269308
Pevonedistat purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2024 Jan 6:34:366-380. [Abstract]
MLN4924 (50-200 nM) can decrease neddylation in RAW264.7 macrophages.
Pevonedistat purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2024 Jan 6:34:366-380. [Abstract]
After overnight culture, RAW264.7 macrophages were subjected to treatment with MLN4924 at concentrations of 0, 0.05, 0.1, and 0.2 μM for 12 h.
-
Nat Microbiol
Proteomic profiling of HIV-1 infection of human CD4+ T cells identifies PSGL-1 as an HIV restriction factor. [Abstract]2019 May;4(5):813-825. PMID: 30833724
Pevonedistat purchased from MedChemExpress. Usage Cited in: Nat Microbiol. 2019 May;4(5):813-825. [Abstract]
293T cells are treated with MLN4924 and then co-transfected with PSGL-1 and Vpu or an empty vector. One day after the transfection, the cells are treated with CHX and collected at the indicated time points. The cell lysates are analysed by western blotting.
Pevonedistat purchased from MedChemExpress. Usage Cited in: Nat Microbiol. 2019 May;4(5):813-825. [Abstract]
293T cells are treated with MLN4924 at the indicated concentrations 24 h before the cells are transfected with plasmids expressing PSGL-1 and Vpu. Two days after transfection, the cells are harvested and analysed by western blotting. Empty vector (–) was used as a negative control for the Vpu- or PSGL-1-expressing vectors.
-
Mol Cell
SMURF2 predisposes cancer cell toward ferroptosis in GPX4-independent manners by promoting GSTP1 degradation. [Abstract]2023 Dec 7;83(23):4352-4369.e8. PMID: 38016474 -
Mol Cell
Micropeptide PACMP inhibition elicits synthetic lethal effects by decreasing CtIP and poly(ADP-ribosyl)ation. [Abstract]2022 Apr 7;82(7):1297-1312.e8. PMID: 35219381 -
Nat Commun
Targeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitors. [Abstract]2026 May 13;17(1):4331. PMID: 42129197 -
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Nat Commun
Transgenerational inheritance of diminished ovarian reserve triggered by prenatal propylparaben exposure in mice. [Abstract]2025 Sep 16;16(1):8289. PMID: 40957879 -
Nat Commun
2025 Jul 24;16(1):6831. PMID: 40707481 -
Nat Commun
CRL3Keap1 E3 ligase facilitates ubiquitin-mediated degradation of oncogenic SRX to suppress colorectal cancer progression. [Abstract]2024 Dec 3;15(1):10536. PMID: 39627198 -
Nat Commun
Coordination of transcription-coupled repair and repair-independent release of lesion-stalled RNA polymerase II. [Abstract]2024 Aug 17;15(1):7089. PMID: 39154022 -
Nat Commun
2024 Jul 3;15(1):5604. PMID: 38961054 -
Nat Commun
2024 Jun 26;15(1):5409. PMID: 38926334 -
Nat Commun
Diabetic sensory neuropathy and insulin resistance are induced by loss of UCHL1 in Drosophila. [Abstract]2024 Jan 11;15(1):468. PMID: 38212312 -
Nat Commun
The E3 ubiquitin ligase ARIH1 promotes antiviral immunity and autoimmunity by inducing mono-ISGylation and oligomerization of cGAS. [Abstract]2022 Oct 10;13(1):5973. PMID: 36217001 -
Nat Commun
Isoform-specific and ubiquitination dependent recruitment of Tet1 to replicating heterochromatin modulates methylcytosine oxidation. [Abstract]2022 Sep 2;13(1):5173. PMID: 36056023 -
Nat Commun
Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer. [Abstract]2021 Sep 10;12(1):5386. PMID: 34508104 -
Nat Commun
2018 Sep 18;9(1):3801. PMID: 30228310
Pevonedistat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Sep 18;9(1):3801. [Abstract]
Trophozoites (3D7) are subjected to the indicated treatment for 6 h before analysis of ubiquitinated proteins. Samples treated with MLN4924 are incubated for an additional 3 h prior to DHA treatment. Blots are representative of 3-4 independent experiments.
-
Nat Commun
pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase. [Abstract]2017 May 22;8:15398. PMID: 28530236 -
Cell Death Differ
Global identification of phospho-dependent SCF substrates reveals a FBXO22 phosphodegron and an ERK-FBXO22-BAG3 axis in tumorigenesis. [Abstract]2022 Jan;29(1):1-13. PMID: 34215846 -
Cell Death Differ
RBX1 prompts degradation of EXO1 to limit the homologous recombination pathway of DNA double-strand break repair in G1 phase. [Abstract]2020 Apr;27(4):1383-1397. PMID: 31562368 -
-
Adv Sci (Weinh)
2026 Apr;13(20):e15159. PMID: 41637562 -
Adv Sci (Weinh)
2025 Oct 5:e03277. PMID: 41047480 -
Adv Sci (Weinh)
Branched-Chain α Keto-Acid Dehydrogenase Kinase-Mediated AKT Phosphorylation Promotes RCC Tumorigenesis and Drug Resistance. [Abstract]2025 Aug 11:e11081. PMID: 40789057 -
Nat Chem Biol
2024 Dec;20(12):1640-1649. PMID: 39075252 -
Nat Chem Biol
2024 Sep;20(9):1227-1236. PMID: 38514884 -
Nat Chem Biol
2024 Jan;20(1):93-102. PMID: 37679459 -
Nat Chem Biol
2023 Dec;19(12):1513-1523. PMID: 37653169 -
Nat Plants
2019 Jan;5(1):34-40. PMID: 30598533
Pevonedistat purchased from MedChemExpress. Usage Cited in: Nat Plants. 2019 Jan;5(1):34-40. [Abstract]
Western analysis of LHCSR1 and LHCSR3 protein expression in the treatment of MLN4924 with different concentrations.
-
Biomaterials
An ultrasound-activated PROTAC prodrug with self-reporting fluorescence for targeted protein degradation. [Abstract]2026 Jul:330:124045. PMID: 41643569 -
Sci Adv
2026 Feb 6;12(6):eadz3483. PMID: 41650254 -
Sci Adv
Neddylation orchestrates the complex transcriptional and posttranscriptional program that drives Schwann cell myelination. [Abstract]2024 Apr 12;10(15):eadm7600. PMID: 38608019 -
Sci Adv
FBXO42 facilitates Notch signaling activation and global chromatin relaxation by promoting K63-linked polyubiquitination of RBPJ. [Abstract]2022 Sep 23;8(38):eabq4831. PMID: 36129980 -
Redox Biol
Cardioprotective effect of MLN4924 on ameliorating autophagic flux impairment in myocardial ischemia-reperfusion injury by Sirt1. [Abstract]2021 Oct:46:102114. PMID: 34454165 -
Cell Rep Med
Neddylation inhibition prevents acetaminophen-induced liver damage by enhancing the anabolic cardiolipin pathway. [Abstract]2024 Jul 16;5(7):101653. PMID: 39019009 -
J Exp Med
CRL4DCAF2 negatively regulates IL-23 production in dendritic cells and limits the development of psoriasis. [Abstract]2018 Aug 6;215(8):1999-2017. PMID: 30018073 -
Nat Struct Mol Biol
2024 Feb;31(2):323-335. PMID: 38177676 -
Cell Death Dis
BRD4 inhibition suppresses histone H4 UFMylation to increase ferroptosis sensitivity through TXNIP. [Abstract]2025 Nov 17;16(1):843. PMID: 41249136 -
Cell Death Dis
DCAF7 recruits USP2 to facilitate hepatocellular carcinoma progression by suppressing clockophagy-induced ferroptosis. [Abstract]2025 Aug 28;16(1):654. PMID: 40877242 -
Cell Death Dis
PRMT1-mediated methylation of UBE2m promoting calcium oxalate crystal-induced kidney injury by inhibiting fatty acid metabolism. [Abstract]2025 Jul 31;16(1):579. PMID: 40744915 -
Proc Natl Acad Sci U S A
Cullin neddylation inhibitor attenuates hyperglycemia by enhancing hepatic insulin signaling through insulin receptor substrate stabilization. [Abstract]2022 Feb 8;119(6):e2111737119. PMID: 35115401 -
Dev Cell
SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. [Abstract]2019 Feb 11;48(3):329-344.e5. PMID: 30595538 -
Int J Biol Macromol
The ubiquitin conjugating enzyme E2 F (UBE2F)-RING-box protein 2 (RBX2)-mediated neddylation of Cullin5 facilitates pseudorabies virus replication. [Abstract]2025 Dec 30:150018. PMID: 41478481 -
Int J Biol Macromol
Z-VAD(OMe)-FMK suppresses Seneca Valley Virus replication by targeting the active sites of the 3C protease. [Abstract]2025 May;306(Pt 3):141587. PMID: 40032110 -
Int J Biol Macromol
2024 Sep 17:135764. PMID: 39299429 -
EMBO J
Cul3-Klhl18 ubiquitin ligase modulates rod transducin translocation during light-dark adaptation. [Abstract]2019 Dec 2;38(23):e101409. PMID: 31696965 -
Cancer Immunol Res
2025 Apr 22. PMID: 40261130 -
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Neoplasia
SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy. [Abstract]2022 Oct:32:100823. PMID: 35907292 -
Cell Chem Biol
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers. [Abstract]2025 Apr 17;32(4):556-569.e24. PMID: 40250405 -
Cell Chem Biol
2021 Oct 21;28(10):1514-1527.e4. PMID: 34314730 -
Cell Death Discov
Neddylation inhibition induces DNA double-strand breaks, hampering tumor growth in vivo, and promotes radiosensitivity in PAX3-FOXO1 rhabdomyosarcoma. [Abstract]2025 Nov 3;11(1):496. PMID: 41184241 -
Cell Death Discov
CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response. [Abstract]2024 Oct 26;10(1):453. PMID: 39461947 -
Cell Death Discov
Neddylation tunes peripheral blood mononuclear cells immune response in COVID-19 patients. [Abstract]2022 Jul 12;8(1):316. PMID: 35831294 -
Cell Death Discov
A novel SRSF3 inhibitor, SFI003, exerts anticancer activity against colorectal cancer by modulating the SRSF3/DHCR24/ROS axis. [Abstract]2022 May 2;8(1):238. PMID: 35501301 -
-
Cell Rep
Harnessing the E3 ligase SPOP for targeted degradation of the NUP98::KDM5A fusion oncoprotein. [Abstract]2025 Nov 25;44(12):116602. PMID: 41307993 -
Cell Rep
Pharmacological inhibition of neddylation impairs long interspersed element 1 retrotransposition. [Abstract]2024 Feb 27;43(2):113749. PMID: 38329876 -
Cell Rep
Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors. [Abstract]2021 Aug 24;36(8):109568. PMID: 34433038 -
Cell Rep
2021 Jul 20;36(3):109394. PMID: 34289372 -
J Med Chem
Discovery and Characterization of a First-In-Class HCK/BTK PROTAC DFCI-002-06 for the Treatment of MYD88 Mutated B Cell Malignancies. [Abstract]2026 Jan 22;69(2):1119-1134. PMID: 41482966 -
J Med Chem
Discovery of DN1679 as a Potent, Orally Bioavailable, and Highly Selective CDK12/13 Dual Degrader for the Treatment of Triple-Negative Breast Cancer. [Abstract]2025 Dec 31. PMID: 41474050 -
J Med Chem
Discovery of Novel, Potent, and Orally Bioavailable SMARCA2 Proteolysis-Targeting Chimeras with Synergistic Antitumor Activity in Combination with Kirsten Rat Sarcoma Viral Oncogene Homologue G12C Inhibitors. [Abstract]2025 Apr 25. PMID: 40280558 -
J Med Chem
First-in-Class Small Molecule Degrader of Pregnane X Receptor Enhances Chemotherapy Efficacy. [Abstract]2024 Oct 24;67(20):18549-18575. PMID: 39405362 -
J Med Chem
Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader. [Abstract]2024 Oct 24;67(20):18247-18264. PMID: 39388374 -
J Med Chem
2024 Aug 8;67(15):12521-12533. PMID: 39047113 -
J Med Chem
Degradation of Cyclin-Dependent Kinase 9/Cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain 3 Beta-Recruiting Coumarin Analogs. [Abstract]2023 Sep 28;66(18):12877-12893. PMID: 37671907 -
J Med Chem
2023 Jul 13;66(13):9184-9200. PMID: 37386884 -
J Med Chem
2023 May 11;66(9):6070-6081. PMID: 36892138 -
J Med Chem
2022 Jan 13;65(1):747-756. PMID: 34965125 -
J Med Chem
Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile. [Abstract]2021 Jul 8;64(13):9152-9165. PMID: 34138566 -
Clin Transl Med
HucMSC-exosomes carrying miR-326 inhibit neddylation to relieve inflammatory bowel disease in mice. [Abstract]2020 Jun;10(2):e113. PMID: 32564521 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Sci Signal
Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors. [Abstract]2025 Feb 11;18(873):eado2857. PMID: 39933019 -
Mol Metab
Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. [Abstract]2021 Nov:53:101275. PMID: 34153521 -
Elife
MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation. [Abstract]2020 Jun 2;9:e54954. PMID: 32484436 -
Elife
Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. [Abstract]2019 Mar 25:8:e45457. PMID: 30907729 -
Elife
Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. [Abstract]2018 Aug 1;7:e38430. PMID: 30067223
Pevonedistat purchased from MedChemExpress. Usage Cited in: Elife. 2018 Aug 1;7:e38430. [Abstract]
Kelly cells are treated with increasing concentrations of Thal and co-treated with 5 μM Bortezonib, 5 μM MLN4924, 0.5 μM MLN7243, or DMSO as a control. Following 24 h incubation, SALL4 and GAPDH protein levels are assessed by western blot analysis.
-
Elife
Lys29-linkage of ASK1 by Skp1-Cullin 1-Fbxo21 ubiquitin ligase complex is required for antiviral innate response. [Abstract]2016 Apr 11;5:e14087. PMID: 27063938
Pevonedistat purchased from MedChemExpress. Usage Cited in: Elife. 2016 Apr 11;5:e14087. [Abstract]
Fbxo21-/- RAW264.7 cells are transfected with indicated amounts (0, 1 or 5 μg) Fbxo21-Myc and equal amounts of K29O-Ub-HA vectors for 48 hr, and then infected with VSV (MOI = 1) or HSV-1 (MOI = 5) for 2 hr in the presence or absence of MLN-4924 (10 nM). Then polyubiquitinated ASK1 is examined by immunoblot (IB) against HA after immuneprecipitations (IP).
-
EMBO Rep
HSC70 coordinates COP9 signalosome and SCF ubiquitin ligase activity to enable a prompt stress response. [Abstract]2025 Mar;26(5):1344-1366. PMID: 39915298 -
Cell Biosci
KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K/PD-L1 axis activity. [Abstract]2020 Nov 27;10(1):139. PMID: 33292627 -
Cell Biol Toxicol
CUL1-neddylation contributes to K29-linked ubiquitination on p27 for autophagic degradation in sorafenib-resistant liver cancer. [Abstract]2025 Mar 20;41(1):61. PMID: 40111576 -
Eur J Med Chem
2023 Nov 15:260:115732. PMID: 37651876 -
Front Immunol
Neddylation Inhibition Causes Impaired Mouse Embryo Quality and Blastocyst Hatching Failure Through Elevated Oxidative Stress and Reduced IL-1β. [Abstract]2022 Jul 4;13:925702. PMID: 35860255 -
Biochem Pharmacol
Discovery of a potent BRD4 PROTAC and evaluation of its bioactivity in breast cancer cell lines. [Abstract]2025 Jul 12:241:117159. PMID: 40659131 -
Biochem Pharmacol
Co-inhibition of BET and NAE enhances BIM-dependent apoptosis with augmented cancer therapeutic efficacy. [Abstract]2024 May:223:116198. PMID: 38588830 -
Neurobiol Dis
Neddylation activity modulates the neurodegeneration associated with fragile X associated tremor/ataxia syndrome (FXTAS) through regulating Sima. [Abstract]2020 Sep;143:105013. PMID: 32653676 -
Virulence
HIV-1 Vpr activates microglia by upregulating m6A modification through ubiquitin-proteasome pathway-mediated degradation of the demethylase ALKBH5. [Abstract]2026 Dec;17(1):2645908. PMID: 41824629 -
Mol Ther Oncolytics
A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer. [Abstract]2020 Jun 23;18:215-225. PMID: 32728610 -
Cells
2021 Oct 20;10(11):2803. PMID: 34831026 -
Protein Sci
Quantitative analyses for effects of neddylation on CRL2VHL substrate ubiquitination and degradation. [Abstract]2021 Nov;30(11):2338-2345. PMID: 34459035 -
J Pathol
2021 Jun;254(2):185-198. PMID: 33638154 -
Cells
Hepatitis B Virus HBx Protein Mediates the Degradation of Host Restriction Factors through the Cullin 4 DDB1 E3 Ubiquitin Ligase Complex. [Abstract]2020 Mar 30;9(4):834. PMID: 32235678 -
Commun Biol
2021 Sep 13;4(1):1066. PMID: 34518642 -
Inflammation
Inhibition of Cullin3 Neddylation Alleviates Diabetic Retinopathy by Activating Nrf2 Signaling to Combat ROS-Induced Oxidative Stress and Inflammation. [Abstract]2025 Mar 1. PMID: 40021543 -
PLoS Pathog
The non-structural protein of SFTSV activates NLRP1 and CARD8 inflammasome through disrupting the DPP9-mediated ternary complex. [Abstract]2025 Jul 3;21(7):e1013258. PMID: 40608794 -
Int J Mol Sci
CRISPR/Cas9 Ribonucleoprotein Delivery Enhanced by Lipo-Xenopeptide Carriers and Homology-Directed Repair Modulators: Insights from Reporter Cell Lines. [Abstract]2025 May 3;26(9):4361. PMID: 40362595 -
Int J Mol Sci
2025 Apr 17;26(8):3790. PMID: 40332396 -
Int J Mol Sci
2023 Feb 8;24(4):3415. PMID: 36834826 -
Int Immunopharmacol
A multi-omics R-loop-linked risk program highlights CKS2-positive proliferative tumor cells as drivers of glioma growth. [Abstract]2026 Apr 15:175:116421. PMID: 41763168 -
Int Immunopharmacol
RICTOR-mediated GPX4 downregulation regulates chondrocyte ferroptosis in osteoarthritis progression. [Abstract]2026 Mar 15:173:116274. PMID: 41605054 -
Eur J Pharmacol
VOPP1, a determinant of the sensitivity of non-small cell lung cancer cells to NAE inhibitors. [Abstract]2025 Sep 15:1003:177942. PMID: 40651787 -
Eur J Pharmacol
Camk2n1 deficiency reduces the NaCl cotransporter activity through the CUL3/KLHL3/WNK4 complex in the kidney. [Abstract]2025 Jan 9:177270. PMID: 39798916 -
Int Immunopharmacol
MLN4924 alleviates autoimmune myocarditis by promoting Act1 degradation and blocking Act1-mediated mRNA stability. [Abstract]2024 Jul 21:139:112716. PMID: 39038386 -
Bioorg Chem
2024 Jun 24:150:107590. PMID: 38955003 -
Mol Cancer Res
The Elongin BC complex negatively regulates AXL and marks a differentiated phenotype in melanoma. [Abstract]2023 May 1;21(5):428-443. PMID: 36753617 -
Biosci Rep
Inhibition of NEDD8 NEDDylation induced apoptosis in acute myeloid leukemia cells via p53 signaling pathway. [Abstract]2022 Aug 31;42(8):BSR20220994. PMID: 35880551 -
Mbio
2020 Jul 14;11(4):e00782-20. PMID: 32665270 -
Cancers
2019 Jan 15;11(1):97. PMID: 30650591 -
Structure
CAND1 and CAND2 drive CUL4 substrate receptor exchange with largely comparable biochemical efficiency, unlike their relative effects on CUL1. [Abstract]2026 Mar 20:S0969-2126(26)00056-0. PMID: 41864201 -
Front Cell Dev Biol
2021 Apr 30:9:667435. PMID: 33996822 -
Lipids Health Dis
MLN4924 inhibits macrophage foam cell formation by enhancing autophagy and regulating metabolic phenotype. [Abstract]2025 Oct 2;24(1):307. PMID: 41039585 -
Biochim Biophys Acta Mol Basis Dis
FBXW8-mediated degradation of PPT1 suppresses epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma. [Abstract]2025 Jul 12;1871(7):167985. PMID: 40659255 -
FASEB J
2021 Aug;35(8):e21800. PMID: 34324733 -
Lab Invest
2019 Apr;99(4):528-538. PMID: 30626891
Pevonedistat purchased from MedChemExpress. Usage Cited in: Lab Invest. 2019 Apr;99(4):528-538. [Abstract]
Western blot analysis of p65 phosphorylation in synovial cells induced by 100 ng/ml IL-17A with or without 100 nM MLN4924 pretreatment.
-
iScience
Latent CSN-CRL complexes are crucial for curcumin-induced apoptosis and recruited during adipogenesis to lipid droplets via small GTPase RAB18. [Abstract]2023 Mar 22;26(4):106468. PMID: 37091236 -
Comput Struct Biotechnol J
Severe fever with thrombocytopenia syndrome virus (SFTSV)-host interactome screen identifies viral nucleoprotein-associated host factors as potential antiviral targets. [Abstract]2021 Oct 1:19:5568-5577. PMID: 34712400 -
J Cell Physiol
2025 Jan;240(1):e31459. PMID: 39373061 -
J Cell Physiol
Neddylation inactivation affects cell cycle and apoptosis in sheep follicular granulosa cells. [Abstract]2022 Aug;237(8):3278-3291. PMID: 35578798 -
J Biol Chem
2026 Jun;302(6):111461. PMID: 41999888 -
Sci Rep
Neddylation status determines the therapeutic sensitivity of tyrosine kinase inhibitors in chronic myeloid leukemia. [Abstract]2025 May 30;15(1):18978. PMID: 40447744 -
Sci Rep
CSP ubiquitylation favours Plasmodium berghei survival during early liver stage infection. [Abstract]2025 Apr 25;15(1):14498. PMID: 40281042 -
J Biol Chem
2024 Jul 1:107512. PMID: 38960037 -
J Biol Chem
A STUB1 ubiquitin ligase/CHIC2 protein complex negatively regulates the IL-3, IL-5, and GM-CSF cytokine receptor common β chain (CSF2RB) protein stability. [Abstract]2022 Oct;298(10):102484. PMID: 36108743 -
J Biol Chem
Neddylation modification of the U3 snoRNA-binding protein RRP9 by Smurf1 promotes tumorigenesis. [Abstract]2021 Nov;297(5):101307. PMID: 34662580 -
J Virol
Cullin 3-mediated ubiquitination restricts enterovirus D68 replication and is counteracted by viral protease 3C. [Abstract]2025 May 21:e0035425. PMID: 40396757 -
J Virol
2024 Feb 20;98(2):e0190923. PMID: 38289118 -
J Virol
Neddylation of Enterovirus 71 VP2 Protein Reduces Its Stability and Restricts Viral Replication. [Abstract]2022 May 25;96(10):e0059822. PMID: 35510863 -
Cell Signal
Targeted degradation of GOLM1 by CC-885 via CRL4-CRBN E3 ligase inhibits hepatocellular carcinoma progression. [Abstract]2025 Jun:130:111665. PMID: 39986359 -
J Cell Sci
Proteasome-dependent Orc6 removal from chromatin upon S-phase entry safeguards against minichromosome maintenance complex reloading and tetraploidy. [Abstract]2025 Jun 18:jcs.263596. PMID: 40554748 -
RSC Med Chem
Structure-guided design of a methyltransferase-like 3 (METTL3) proteolysis targeting chimera (PROTAC) incorporating an indole-nicotinamide chemotype. [Abstract]2025 Jun 19. PMID: 40599585 -
Viruses
Identification of Adenovirus E1B-55K Interaction Partners through a Common Binding Motif. [Abstract]2023 Nov 30;15(12):2356. PMID: 38140597 -
Exp Cell Res
Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27Kip1. [Abstract]2020 Jul 15;392(2):112038. PMID: 32360865 -
Am J Physiol Lung Cell Mol Physiol
MLN4924 protects against interleukin-17A-induced pulmonary inflammation by disrupting ACT1-mediated signaling. [Abstract]2019 Jun 1;316(6):L1070-L1080. PMID: 30892082
Pevonedistat purchased from MedChemExpress. Usage Cited in: Am J Physiol Lung Cell Mol Physiol. 2019 Jun 1;316(6):L1070-L1080. [Abstract]
Immunoblotting analysis of degradation of IκBα, and levels of p-p65 (also known as RELA) and the NEDD8–Cullin compared with β-actin and total p65 in cell lysates from pulmonary epithelial cells stimulated with rmIL-17A (50 ng/ml) for 15 min after preincubation with the indicated concentration of MLN4924 (MLN) or DMSO for 0.5 h.
Pevonedistat purchased from MedChemExpress. Usage Cited in: Am J Physiol Lung Cell Mol Physiol. 2019 Jun 1;316(6):L1070-L1080. [Abstract]
Immunoblotting analysis of p-p38, JNK, and ERK compared with total p38, JNK, and ERK in cell lysates from pulmonary epithelial cells stimulated as above.
-
Am J Physiol Lung Cell Mol Physiol
2017 Jul 1;313(1):L104-L114. PMID: 28522566 -
J Immunol
Neddylation Alleviates Methicillin-Resistant Staphylococcus aureus Infection by Inducing Macrophage Reactive Oxygen Species Production. [Abstract]2021 Jul 1;207(1):296-307. PMID: 34183370 -
Cell Cycle
The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors. [Abstract]2019 Sep;18(18):2307-2322. PMID: 31349760 -
Front Oncol
Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. [Abstract]2022 Jan 26;12:822039. PMID: 35155257 -
Front Oncol
2017 Dec 11:7:293. PMID: 29322028 -
Int J Med Sci
Inhibition of CRL-NEDD8 pathway as a new approach to enhance ATRA-induced differentiation of acute promyelocytic leukemia cells. [Abstract]2018 Apr 3;15(7):674-681. PMID: 29910671
Pevonedistat purchased from MedChemExpress. Usage Cited in: Int J Med Sci. 2018 Apr 3;15(7):674-681. [Abstract]
NB4 cells are treated with MLN4924 (0, 20, 40 and 80 nM) for 0, 24, 48 and 72 hours, and the protein levels of cullin1 are detected by western blotting, with β-actin used as loading control.
-
Arch Biochem Biophys
Chemical degrader enhances the treatment of androgen receptor-positive triple-negative breast cancer. [Abstract]2022 May 30;721:109194. PMID: 35337811 -
Arch Biochem Biophys
Dysfunction of Cullin 3 RING E3 ubiquitin ligase causes vasoconstriction and increased sodium reabsorption in diabetes. [Abstract]2021 Oct 15:710:109000. PMID: 34343486 -
J Anim Sci
Ubiquitination plays an important role during the formation of chicken primordial germ cells. [Abstract]2024 Jan 3:102:skae251. PMID: 39187982 -
Technol Cancer Res Treat
Radiosensitization of Human Colorectal Cancer Cells by MLN4924: An Inhibitor of NEDD8-Activating Enzyme. [Abstract]2016 Aug;15(4):527-34. PMID: 26082455
Pevonedistat purchased from MedChemExpress. Usage Cited in: Technol Cancer Res Treat. 2016 Aug;15(4):527-34. [Abstract]
MLN4924 induces accumulation of SCF E3 ligase substrates. Subconfluent cells are treated with MLN4924 (50 nM) or radiation (6 Gy) alone or in combination for 24 hours, followed by immunoblotting (IB) analysis using indicated antibodies.
-
Theriogenology
Neddylation inhibition affects cell proliferation and steroidogenesis in sheep follicular granulosa cells. [Abstract]2025 Apr 15:237:99-109. PMID: 39986219 -
Virology
Determinants for degradation of SAMHD1, Mus81 and induction of G2 arrest in HIV-1 Vpr and SIVagm Vpr. [Abstract]2015 Mar;477:10-7. PMID: 25618414 -
Ann Hematol
Bone marrow mesenchymal stromal cells affect the cell cycle arrest effect of genotoxic agents on acute lymphocytic leukemia cells via p21 down-regulation. [Abstract]2014 Sep;93(9):1499-508. PMID: 24705889
Pevonedistat purchased from MedChemExpress. Usage Cited in: Ann Hematol. 2014 Sep;93(9):1499-508. [Abstract]
MLN4924-induced p21 high expression eliminates the cell cycle promotion effect of BM-MSCs on Reh cells. a Western blot analysis of p21, skp2, and bax expression in Reh cells treated by different concentration of MLN4924. b Under the treatment of 25 nM IDA, western blot analysis of p21 and skp2 expressions in Reh cells cultured with or without BM-MSCs in the presence of different concentrations of MLN4924 (0, 300, 700 nM). c Under the treatment of 250 nM VP16, western blot analysis of p21 and skp
-
Cancer Chemother Pharmacol
A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification. [Abstract]2018 Jun;81(6):1083-1093. PMID: 29667067
Pevonedistat purchased from MedChemExpress. Usage Cited in: Cancer Chemother Pharmacol. 2018 Jun;81(6):1083-1093. [Abstract]
786-0 and ACHN cells are treated with MLN4924 (0.5 μM or 1 μM).γ-H2AX is detected by immunoblotting analysis.
-
Biochim Biophys Acta Gen Subj
2025 Sep;1869(10):130842. PMID: 40664338 -
Biochem Biophys Res Commun
Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma. [Abstract]2021 Apr 16:549:150-156. PMID: 33676183 -
Oncol Lett
An overactive neddylation pathway serves as a therapeutic target and MLN4924 enhances the anticancer activity of cisplatin in pancreatic cancer. [Abstract]2019 Sep;18(3):2724-2732. PMID: 31404297 -
Biochem Biophys Res Commun
Adenovirus oncoprotein E4orf6 triggers Cullin5 neddylation to activate the CLR5 E3 ligase for p53 degradation. [Abstract]2019 Sep 3;516(4):1242-1247. PMID: 31301771 -
Biochem Biophys Res Commun
Disruption of protein neddylation with MLN4924 attenuates paclitaxel-induced apoptosis and microtubule polymerization in ovarian cancer cells. [Abstract]2019 Jan 15;508(3):986-990. PMID: 30545630
Pevonedistat purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2019 Jan 15;508(3):986-990. [Abstract]
MLN4924 antagonizes the suppressive effects of PTX on cytoskeletal organization in HO8910 and OVA-W cells. (A, C) After treatment with PTX and/or MLN4924 for 48 h, HO8910 and OVA-W cells are stained for α-tubulin and analyzed for intracellular distribution by confocal microscopy. Overlay of blue (nuclei) and red (a-tubulin) channels is shown. (B, D) Levels of α-tubulin protein are further confirmed by western blotting with b-actin as the loading control.
-
Biochem Biophys Res Commun
2018 Nov 17;506(1):108-113. PMID: 30340827 -
Biochem Biophys Res Commun
2017 Jan 29;483(1):223-229. PMID: 28034751 -
Biosci Biotechnol Biochem
Synergistic effect of cerium chloride and calcium chloride alters calcium signaling in keratinocytes to promote epidermal differentiation. [Abstract]2024 Nov 22;88(12):1432-1441. PMID: 39333009 -
-
bioRxiv
2026 May 14:2026.05.12.724395. PMID: 42182270 -
-
-
-
-
-
bioRxiv
Unbiased CRISPR Synthetic Lethal Screening for Genetic Vulnerabilities in Succinate Dehydrogenase (SDH)-loss Model of Paraganglioma. [Abstract]2025 Aug 28:2025.08.26.672429. PMID: 40909557 -
bioRxiv
2025 Aug 14:2025.08.14.670414. PMID: 40832228 -
bioRxiv
Development of Degraders and 2-pyridinecarboxyaldehyde (2-PCA) as a recruitment Ligand for FBXO22. [Abstract]2025 Aug 20:2025.08.19.671158. PMID: 40894587 -
-
-
-
bioRxiv
2025 May 15:2025.05.10.653233. PMID: 40463067 -
-
-
-
-
bioRxiv
2024 Sep 27:2024.09.25.615094. PMID: 39386645 -
-
bioRxiv
Pharmacological Inhibition of Epac1 Protects against Pulmonary Fibrosis by Blocking FoxO3a Neddylation. [Abstract]2024 Sep 19:2024.09.13.612935. PMID: 39345579 -
-
-
-
-
-
-
-
-
-
bioRxiv
Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders. [Abstract]2023 Feb 15:2023.02.14.528208. PMID: 36824856 -
bioRxiv
Inducible mismatch repair streamlines forward genetic approaches to target identification of cytotoxic small molecules. [Abstract]2023 Feb 21:2023.02.21.529401. PMID: 36865268 -
-
-
-
-
-
-
-
-
-
Eur Rev Med Pharmacol Sci
MRFAP1 plays a protective role in neddylation inhibitor MLN4924-mediated gastric cancer cell death. [Abstract]2018 Dec;22(23):8273-8280. PMID: 30556867
Pevonedistat purchased from MedChemExpress. Usage Cited in: Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8273-8280. [Abstract]
AGS cells are transfected with increased dose of Flag-FBXW8 for 30 hours, 2 μM MLN4924 are added where indicate 4 hours before harvested. Western blot assay is performed with indicated antibodies.
Pevonedistat purchased from MedChemExpress. Usage Cited in: Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8273-8280. [Abstract]
MRFAP1 KO AGS cells are treated with or without 2 μM MLN4924 for 24 hours, cells are harvested and subjected to Western blot with indicated antibodies.
Pevonedistat purchased from MedChemExpress. Usage Cited in: Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8273-8280. [Abstract]
AGS cells are transfected with Flag-MRFAP1 for 30 hours and treated with or with 2 μM MLN4924 for additional 4 hours, cells are harvested and subjected to immunoprecipitation with Flag M2 beads and then detected with Western blot.
-
-
Oncotarget
2017 Oct 12;8(57):97178-97186. PMID: 29228602
Pevonedistat purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Oct 12;8(57):97178-97186. [Abstract]
After 4 hours 1 µM MLN4924 treatment, lysates from 293T cells stably expressing either Flag or Flag-FBXW8 are immunoprecipitated with anti-FLAG M2 resin. Bound proteins are eluted with FLAG peptide, and all separated cell lysate components are resolved on 10% SDS-PAGE gel, stained by Coomassie Brilliant or subjected to immunoblotting with the indicated antibodies.
-
Oncotarget
2017 Sep 23;8(49):86395-86409. PMID: 29156803
Pevonedistat purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Sep 23;8(49):86395-86409. [Abstract]
Immunofluorescence results, showing that ROC1, DCAF1, DDB1, and TET1 knockdown, and treatment with MLN4924 leads to the reduction of 5hmC levels in A2780 cells. A2780 cells transfected with siNC, siROC1, siDCAF1, siDDB1 or siTET1 and treatment with MLN4924 are subjected to immunofluorescence analysis with antibodies to the indicated protein.
-
-
Oncotarget
Circadian clock components RORα and Bmal1 mediate the anti-proliferative effect of MLN4924 in osteosarcoma cells. [Abstract]2016 Oct 4;7(40):66087-66099. PMID: 27602774
Pevonedistat purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 Oct 4;7(40):66087-66099. [Abstract]
MLN4924 increases the stability of RORα. MLN4924 increases the half-life of RORα. U2OS cells are transiently transfected with plasmids expressing the Flag-RORα. At 24 h after transfection, MLN4924 (1 μM) or DMSO are added into respective cell culture media. 24 h later, cells are treated with Cycloheximide (CHX) for 0, 3, 6, 4, 9 and 12 h. Equal amounts of whole cell lysates are analyzed by Western blot with a Flag antibody (M2). Actin is used as an internal control.
-
Oncotarget
Inhibition of neddylation regulates dendritic cell functions via Deptor accumulation driven mTOR inactivation. [Abstract]2016 Jun 14;7(24):35643-35654. PMID: 27224922
Pevonedistat purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 Jun 14;7(24):35643-35654. [Abstract]
MLN4924 induces apoptosis is caspase dependent. BMDCs are cultured with MLN4924. Total cellular protein extracts are prepared and subjected to immunoblotting by using A. anti-PARP, anti-caspase-3, anti-caspase-7 antibodies and B. anti-cleaved PARP, anti-cleaved-caspase-3, anti-cleaved-caspase-7 antibodies. C. Caspase-3 activity is examined by caspase activity kit. D. Immunoblotting analysis is performed for erk, p-erk, cyclin D1 and cyclin D3 expression.
Solvent & Solubility
DMSO : 62.5 mg/mL (140.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% Saline
Solubility: 5 mg/mL (11.27 mM); Suspended solution; Need ultrasonic
Add each solvent one by one: 5% DMSO 95% Saline
Solubility: 2.5 mg/mL (5.64 mM); Suspended solution; Need ultrasonic
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.69 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.69 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 1% DMSO 99% Saline
Solubility: 0.5 mg/mL (1.13 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
HCT-116 cells grown in 6-well cell-culture dishes are treated with 0.1% DMSO (control) or 0.3 μM Pevonedistat (MLN4924) for 24 h. Whole cell extracts are prepared and analysed by immunoblotting. For analysis of the E2-UBL thioester levels, lysates are fractionated by non-reducing SDS-PAGE and immunoblotted with polyclonal antibodies to Ubc12, Ubc9 and Ubc10. For analysis of other proteins, lysates are fractionated by reducing SDS-PAGE and probed with primary antibodies as follows: mouse monoclonal antibodies to CDT1, p27, geminin, ubiquitin, securin/PTTG and p53 or rabbit polyclonal antibodies to NRF2, Cyclin B1 and GADD34[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[1]
Mice bearing HCT-116 tumours of 300-500 mm3 are administered a single Pevonedistat (MLN4924) dose (of 10, 30 or 60 mg/kg), and tumors are excised at various time-points over the subsequent 24 h period. The relative levels of NEDD8-cullin and NRF2 are estimated by quantitative immunoblot analysis using Alexa680-labelled anti-IgG as the secondary antibody. The statistical difference between the groups for NEDD8-cullin inhibition is determined using the Kruskal-Wallis test. For the analysis of CDT1 and phosphorylated CHK1 (Ser317) levels in tumour sections, formalin-fixed, paraffin-embedded tumour sections are stained with the relevant antibodies, amplified with HRP-labelled secondary antibodies and detected with the ChromoMap DAB Kit. Slides are counterstained with haematoxylin. Images are captured using an Eclipse E800 microscope and Retiga EXi colour digital camera and processed using Metamorph software. CDT1 and phosphorylated CHK1 levels are expressed as a function of the DAB signal area.
Rats[2]
Ten-week-old male Sprague-Dawley rats are used. Across two studies, a total of eight animals in each group are dosed with vehicle, TNF-α, Pevonedistat (MLN4924), or Pevonedistat (MLN4924)+TNF-α. Animals are first intravenously administered either vehicle (1×PBS) or 10 μg/kg TNF-α. One hour later, they are subcutaneously administered vehicle (20% sulfobutyl ether beta-cyclodextrin in 50 mM citrate buffer, pH 3.3) or 120 mg/kg Pevonedistat (MLN4924). Scheduled euthanasia occurred 24 h postdose. Unscheduled euthanasia is performed when animals exhibited moribund conditions. Serum is collected at necropsy and analyzed by Idexx Laboratories for serum chemistry markers of liver damage. Additionally, the livers from five animals in each group are removed, separated into two sections and either frozen at -80°C for subsequent protein analysis or fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at 4-6 μm, mounted on glass slides, stained with hematoxylin and eosin, and analyzed with an Olympus BX51 light microscope for histopathology assessment. Microscopic findings are recorded in concordance with the standardized nomenclature for classifying lesions within the livers of rats.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2547 mL | 11.2734 mL | 22.5469 mL | 56.3672 mL |
| 5 mM | 0.4509 mL | 2.2547 mL | 4.5094 mL | 11.2734 mL | |
| 10 mM | 0.2255 mL | 1.1273 mL | 2.2547 mL | 5.6367 mL | |
| 15 mM | 0.1503 mL | 0.7516 mL | 1.5031 mL | 3.7578 mL | |
| 20 mM | 0.1127 mL | 0.5637 mL | 1.1273 mL | 2.8184 mL | |
| 25 mM | 0.0902 mL | 0.4509 mL | 0.9019 mL | 2.2547 mL | |
| 30 mM | 0.0752 mL | 0.3758 mL | 0.7516 mL | 1.8789 mL | |
| 40 mM | 0.0564 mL | 0.2818 mL | 0.5637 mL | 1.4092 mL | |
| 50 mM | 0.0451 mL | 0.2255 mL | 0.4509 mL | 1.1273 mL | |
| 60 mM | 0.0376 mL | 0.1879 mL | 0.3758 mL | 0.9395 mL | |
| 80 mM | 0.0282 mL | 0.1409 mL | 0.2818 mL | 0.7046 mL | |
| 100 mM | 0.0225 mL | 0.1127 mL | 0.2255 mL | 0.5637 mL |